ardiology Science Lunch erlin - Charite
1
Cardiology Science Lunch Berlin a weekly exchange of insights and ideas in cardiovascular medicine Campus Virchow Klinik Wednesday , 24.05.2017 12:00 – 13:00h Bibliothek at DHZB Augustenburger Platz 1, Berlin x Bibliothek The following CSLB is on 31.05.2017 Cardiology Science Lunch Berlin is sponsored by www.sciencelunch.de Prof. Dr. med. Veselin Mitrovic Kerckhoff-Klinik Forschungsgesellschaft, Bad Nauheim New Drugs and Perspectives in Treating Acute Heart Failure Therapies for managing ADHF are far from ideal: Hospitalization rates and disease mortality continue to increase, whereas current pharmacotherapy has its limitations. As of today, no randomized trial has demonstrated a beneficial effect of any drug on ADHF prognosis. Thus, there is still a urgent need for better therapies. Several drug classes have been developed to correct or mitigate disordered pathways and, thereby, preserve and protect myocytes. Such are natriuretic peptides, modulators of soluble and particulate guanylate cyclase, the vasoactive peptide serelaxin, HNO prodrugs, etc. Prof. Mitrovic will discuss the role of vasoactive drugs in the management of ADHF. The Cardiology Science Lunch Team from the Department of Cardiology, Charité Universitätsmedizin, Campus Virchow-Klinikum, Berlin and the Department of Medicine/Cardiology, Deutsches Herzzentrum Berlin Prof. Dr. med. Frank R. Heinzel, Ph.D. Dr. med. Tobias Trippel PD. Dr. Florian Blaschke Dr. Paulina Wakuła, Ph.D. Christina Gaulhofer, BSc. MSc. Prof. Dr. med. Philipp Stawowy Univ. Prof. Dr. med. Burkert Pieske
Transcript of ardiology Science Lunch erlin - Charite
Cardiology Science Lunch Berlina weekly exchange of insights and ideas in cardiovascular medicine
Campus Virchow Klinik
Wednesday, 24.05.2017
12:00 – 13:00h
Bibliothek at DHZBAugustenburger Platz 1, Berlin
x Bibliothek
The following CSLB is on 31.05.2017
Cardiology Science Lunch Berlin
is sponsored by
www.sciencelunch.de
Prof. Dr. med. Veselin MitrovicKerckhoff-Klinik Forschungsgesellschaft, Bad Nauheim
New Drugs and Perspectives in Treating Acute Heart Failure
Therapies for managing ADHF are far from ideal: Hospitalization rates anddisease mortality continue to increase, whereas current pharmacotherapyhas its limitations.As of today, no randomized trial has demonstrated a beneficial effect of anydrug on ADHF prognosis. Thus, there is still a urgent need for bettertherapies. Several drug classes have been developed to correct or mitigatedisordered pathways and, thereby, preserve and protect myocytes. Such arenatriuretic peptides, modulators of soluble and particulate guanylatecyclase, the vasoactive peptide serelaxin, HNO prodrugs, etc.Prof. Mitrovic will discuss the role of vasoactive drugs in the management ofADHF.
The Cardiology Science Lunch Teamfrom the Department of Cardiology, Charité Universitätsmedizin, Campus Virchow-Klinikum, Berlinand the Department of Medicine/Cardiology, Deutsches Herzzentrum Berlin
Prof. Dr. med. Frank R. Heinzel, Ph.D.Dr. med. Tobias TrippelPD. Dr. Florian Blaschke
Dr. Paulina Wakuła, Ph.D.Christina Gaulhofer, BSc. MSc.Prof. Dr. med. Philipp Stawowy
Univ. Prof. Dr. med. Burkert Pieske
